Median Technologies unveils a new identity, including a new name, logo, tagline for its iBiopsy® AI/ML tech-based suite of software as medical devices and business unit, as part of an extensive rebranding initiative.
Median Technologies Announces Rebranding of iBiopsy®, Changes Name to eyonis™ Read More »
Konica Minolta Healthcare Americas, Inc., announced several new solutions in digital radiography and ultrasound that will be introduced at the 2023 Radiology Society of North America Scientific Assembly and Annual Meeting from November 26-30 in Chicago, IL.
Mesoblast Limited announced that it has filed for orphan drug designation and rare pediatric disease designation with the United States Food and Drug Administration for its allogeneic cell therapy Revascor® in the treatment of the congenital heart disease hypoplastic left heart syndrome.
While Amgen and Mirati are widely viewed as frontrunners to win the first front line approval, analysts—and competitors—say the field is still wide open.
Mirati, Amgen, Lilly and More Race to the Front Line in KRAS-Mutated NSCLC Read More »
As companies clamor for a piece of the antibody-drug conjugate pie, experts pose the question: is it possible to replicate the success of Enhertu?
Next-Generation ADCs Strive to Overcome Toxicities, Payload Problems Read More »
Las estrategias y herramientas para predecir y retrasar la progresión a la enfermedad renal terminal son vitales
Una guía rápida para la práctica | Abordaje de la enfermedad renal crónica en el anciano Read More »
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the Company has received notice from The Nasdaq Capital Market, LLC (“Nasdaq”), dated November 22, 2023, informing Novo that it has regained compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing on Nasdaq.
Novo Integrated Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement Read More »
GenFleet Therapeutics today announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for GFH925.
Ascentage Pharma hosted a ceremony in Suzhou, China, marking the launch of olverembatinib in a newly approved indication and the dispatch of the first batch of the drug for the new indication.
Novartis is conducting a voluntary nationwide recall at the consumer level of two lots of its Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL in the US due to crystal formation observed in some bottles, which could potentially result in incorrect dosing.
